Theriva Biologics sells antibiotic-degrading enzyme portfolio to Biossil Labs

PUBT · 1d ago
Theriva Biologics sells antibiotic-degrading enzyme portfolio to Biossil Labs
  • Theriva Biologics sold its antibiotic-degrading enzyme portfolio, including SYN-004 (ribaxamase), to Toronto-based Biossil Labs.
  • The seller received $350,000 upfront at closing.
  • Potential milestone payments total $91 million: up to $3 million for regulatory achievements and $88 million tied to cumulative worldwide net sales.
  • Low single-digit royalties on net product sales are capped at $250 million.
  • Biossil assumed all responsibility and costs for future development and commercialization of the acquired portfolio.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theriva Biologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611020800OMX_____CNEWS_EN_GNW9857404_en) on November 02, 2026, and is solely responsible for the information contained therein.